The global sales of artificial pancreas device systems are estimated to be worth USD 374.3 million in 2025 and are anticipated to reach USD 875.3 million by 2035. Sales are projected to rise at a CAGR of 8.7% over the forecast period between 2025 and 2035. The revenue generated by the artificial pancreas device system in 2024 was USD 343.5 million.
APDS holds great promise as an innovative advancement for diabetes management optimized solutions for the automatic maintenance of normal blood glucose levels. APDS encompasses a combination of insulin pumps, CGMs, and elaborate control algorithms aimed at emulating the function of a healthy pancreas.
Most diabetes type I patients, mainly dependent on constant insulin administration, have been managed with these devices; more are being adopted by insulin-dependent Type 2 diabetics, with very few utilized by those with gestational diabetes.
Rapid market growth has been fostered by the increasing prevalence of diabetes and globally rising obesity, all adding up to increased demand for innovative solutions in diabetes management. APDS will be less invasive, with better glycemic control, and will be more convenient for patients compared to the conventional methods of glucose monitoring and insulin delivery.
Intense R&D efforts by industry players and advancements in sensor technology further propel market expansion, making APDS a cornerstone in modern diabetes care.
Global Artificial Pancreas Device System Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 343.5 million |
| Estimated Size, 2025 | USD 374.3 million |
| Projected Size, 2035 | USD 875.3 million |
| Value-based CAGR (2025 to 2035) | 8.7% |
Several interrelated factors contribute to the growing market for APDS, reflecting care burdens due to diabetes and technological advancements in medical care. The fastest rising, among these others, is diabetes incidence in global settings.
The players in this industry heavily invest in R&D to perfect and advance the methods and technologies of APDS. Most clinical studies optimize blood glucose management to ensure that the device's intended use is achieved; among those studies, there are ones on device accuracy, reliability, and user-friendliness.
The combination of these efforts has resulted in tremendous jumps in the development of better CGMs, insulin pumps, and algorithmic control systems that could be implemented for the seamless and automated management of diabetes.
APDS, providing less invasive, more efficient management options for the patient while minimizing the degree to which human intervention becomes necessary, is poised for presentation into the market.
Apart from the geriatric population, the rising obese economy is a significant factor determining the growth of this market. Obesity remains one of the leading risk factors for Type 2 diabetes and an exacerbation of Type 1 diabetes.
Hence, the increasing global obesity epidemic has raised huge demands for newer advances in diabetes management systems, with APDS as one of the preferred alternatives since it works on automation and is more efficient.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The compound annual growth rate (CAGR) of the global market for artificial pancreas device systems for the first half of 2024 and 2025 is compared in the table below. This analysis provides important insights into the performance of the industry by highlighting significant shifts and trends in revenue generation.
The first half (H1) is the period from January to June, and the second half (H2) is July to December. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 9.6%, followed by a slightly lower growth rate of 9.3% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 9.6% (2024 to 2034) |
| H2 | 9.3% (2024 to 2034) |
| H1 | 8.9% (2025 to 2035) |
| H2 | 8.4% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 8.9% in the first half and remain relatively moderate at 8.4% in the second half. In the first half (H1) the industry witnessed a decrease of 70 BPS while in the second half (H2), the industry witnessed a decrease of 90 BPS.
Rising Prevalence of Diabetes is Driving Artificial Pancreas Device System Sales
According to the International Diabetes Federation, there are more than 460 million patients with diabetes worldwide, a number anticipated to grow over the coming years and decades. This worrying increase has heightened the need for advanced technologies such as APDS to promote glycemic control and enhance patient outcomes.
Diabetes, especially Type 1 and insulin-dependent Type 2, must be managed on an ongoing basis to prevent complications such as cardiovascular disease, kidney damage, and nerve disorders. APDS has emerged as the transformative solution, offering automated, real-time blood glucose monitoring and insulin delivery that closely emulates the natural function of a healthy pancreas.
With the world healthcare community moving towards innovative ways to manage this chronic condition, APDS has been accepted because it eases the burden of disease management by the patient and improves their quality of life.
Furthermore, the increasing prevalence of diabetes among younger populations, added to the rising obesity rates and the aging demographic, emphasizes the critical demand for such devices. Heavy investment in APDS technology by governments, healthcare providers, and private companies is taking place to answer this growing crisis, thus making it one of the pivotal tools in the global fight against diabetes.
The Market Is Experiencing Significant Growth Due to the Technological Advancements in Artificial Pancreas Device System
Improvements in technology have considerably improved the efficiency, reliability, and usability of APDS. Innovations related to CGM systems now yield more accurate, real-time glucose readings that are quite crucial for efficient glycemic control.
In like manner, insulin delivery pumps are becoming more accurate, compact, and user-friendly to afford patients a better level of comfort and convenience. The APDS is based on a platform of sophisticated control algorithms that achieves fully integrated coordination between CGMs and insulin pumps, enabling highly responsive and automated glucose regulation in a manner very similar to a healthy pancreas.
In addition to the core components mentioned, some of the innovative features, such as smartphone integration, Bluetooth connectivity, and cloud-based data storage, have attracted a new population of patients and healthcare providers who are interested in using APDS.
Now, with the new technology, the devices allow the tracking of glucose levels and insulin delivery via mobile apps, thus allowing users to garner personalized insights and facilitate communication with healthcare professionals more easily.
Additionally, AI-powered predictive analytics enhance APDS functionality by predicting glucose trends and preventing hypo- and hyperglycemic events.
This advancement has increased the effectiveness, adoption, and accessibility of APDS devices. These innovations will allow patients to better and more easily manage diabetes by themselves and thus improve the quality of their lives due to reduced user intervention and real-time data.
Integration of Smartphone and Wearable Technology and its Impact on this Market is emerging as a Significant Trend for the Market.
The increasing demand for user-friendly interfaces has driven the integration of smartphone applications and wearable devices with APDS. Indeed, these integrations have revolutionized the management of diabetes by offering real-time access to critical health data, which was earlier limited.
Thus, patients can now monitor glucose levels, track insulin delivery, and observe trends directly from their smartphones or wearable gadgets, leading to a great increase in adherence to treatment protocols and convenience.
Wearable devices like smartwatches and fitness trackers have made instant alerts for hypo- or hyperglycemia possible, which, in turn, allows the patients to take timely action and prevent further complications. Besides, Bluetooth connectivity enables smooth synchronization across devices for continuous and accurate glucose monitoring.
The more advanced applications attributed to APDS devices include artificial intelligence-powered predictive analytics, enabling personalized recommendations to achieve improved glycemic control.
These range from the application being able to forecast possible changes in blood glucose in relation to a user's activities, diet, and insulin use, among others, in advance, hence empowering them to act appropriately.
Regulatory Challenges and Approval Process Delays May Restrict Market Growth
One of the significant challenges of the artificial pancreas device system is the regulatory hurdles involved. It would require a few stages to obtain regulatory approval towards dimension, out of which some may include preclinical trials, clinical studies, post-market surveillance, and more, each requiring extensive evidence and documentation to show safety, efficacy, and performance.
Regulatory bodies like the USA FDA and EMA have, therefore, set strict standards to ensure these devices will not impose any hazard to the patients, and that becomes particularly important when considering the nature of APDS devices that regulate critical functions, such as insulin delivery.
The process is very long and expensive for manufacturers. Clinical trials, which are usually a prerequisite for approval, take many years to complete and delay the entry of new technologies into the market. Extended timelines for approval raise overall development costs for companies, which may impact pricing and access to the market.
Besides, the very process of approval may vary greatly from region to region, which creates additional obstacles for companies willing to bring their products onto the international market.
Some regions can have less strict requirements, but these standard variations may not allow APDS devices to enter different markets smoothly, leading to delays or even hindering market extension.
The global artificial pancreas device system industry recorded a CAGR of 8.2% during the historical period between 2020 and 2024. The growth of artificial pancreas device system industry was positive as it reached a value of USD 875.3 million in 2035 from USD 374.3 million in 2025.
Advanced technologies for the management of diabetes have been one of the major reasons for significant growth in the APDS market in the last decade. It started with simple insulin pumps and basic glucose monitors but has rapidly grown into integrated systems offering automated glycemic control.
The growth has resulted from the increasing prevalence of Type 1 diabetes, heightened awareness of healthcare, and increased regulatory clearances for advanced systems.
The continuous rise in cases of diabetes, especially Type 1, along with increasing advances in sensor technology, insulin delivery, and data analytics, is expected to further expand the APDS market. Growing demand for wearable and connected solutions is also an important factor in market growth.
However, at the same time, high device costs remain a challenge in addition to regulatory hurdles and the need for wide acceptance in healthcare as potential barriers. However, with all such challenges, the future for players in the APDS market looks bright.
Continuous developments and improvements in Artificial Intelligence and machine learning will yield more efficient and easy-to-handle yet reachable systems for glucose management.
Tier 1 companies dominate the market, gaining the highest share of about 57.3% from their superior technological offerings and massive investments in R&D. Some of the noted players in this tier include Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., and Abbott Laboratories.
Tier 2 companies have significant market shares of about 21.5%, and revenues generally range between USD 90 million and USD 130 million per year. Some of the most important companies in this category are Beta Bionics, BigFoot Biomedical Inc., Diabeloop SA, and EoFlow Co. Ltd.
These are the minor players or niche-focused firms working on innovative solutions for artificial pancreas device systems. Although their share in the market is negligible, they are significant in proving specific demands and innovations in artificial pancreas device systems.
These three tiers form the competitive landscape of the artificial pancreas device system market - Tier 1 companies advance on high-tech fronts, Tier 2 companies concentrate in niche markets, and Tier 3 companies bring innovation into the market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the industry analysis of artificial pancreas device systems in different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 3.6% through 2035. In Asia Pacific, China is projected to witness a CAGR of 6.0% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 3.6% |
| Germany | 4.1% |
| France | 5.9% |
| UK | 4.5% |
| China | 6.0% |
| India | 9.2% |
Germany’s artificial pancreas device system market is expected to exhibit a CAGR of 4.1% between 2025 and 2035. Germany holds the highest market share in the European market.
In Germany, the market is driven by the country's high prevalence of diabetes and increasing consumer focus on preventive healthcare. With around 9% of its adult population being diabetic, Germany is home to one of the largest populations in Europe affected by diabetes. It has developed a large requirement for artificial pancreas device systems.
The German healthcare system has emphasized self-management of chronic diseases, such as diabetes, consistent with the increasing penetration of artificial pancreas device systems. Besides, the well-defined regulatory regime in Germany offers high-quality, accurate artificial pancreas device systems that promote fulfilling requirements and provide effective solutions.
The United States market is anticipated to grow at a CAGR of 3.6% throughout the forecast period.
In the United States, reimbursement policies are essential in expanding access to health technologies, such as artificial pancreas device systems. With time, Medicare, Medicaid, and private health insurance providers are recognizing their value and increasing the use of APDS as an integral part of diabetes care.
This recognition thus helps the APDS device to reach the mass majority, including patients with Type 1 and Type 2 diabetes who require continuous monitoring and insulin delivery.
Including APDS devices under reimbursement policies reduces the out-of-pocket expenses for patients who otherwise have to bear the exorbitant costs of these advanced systems.
In the context of diabetes care, long-term management requires continuous glucose monitoring and insulin delivery systems, which could be quite expensive. Thus, covering APDS devices under insurance helps patients afford such life-saving technologies, improving adherence to diabetes treatment plans and better health outcomes.
India is expected to hold a dominating position in the South Asia market of artificial pancreas device systems. It is anticipated to grow at a CAGR of 9.2% throughout the forecast period.
The increasing prevalence of diabetes among the population is creating a demand for affordable remedies in India, which, in turn, drives the industry toward the primary demand for artificial pancreas device systems.
Many of the population lives in rural or semi-urban areas, and healthcare is inaccessible and largely unaffordable. Thus, growing adoptions of an APDS at the expense of more economically constructive options activate the segment's revenues.
The local manufacturers in India are trying to make APDS more affordable by developing budget-friendly versions, and hence, the technology is becoming more accessible to the general population. These devices are often designed to meet the basic needs of diabetes management without compromising essential features such as insulin delivery and glucose monitoring.
The section contains information about the leading segments in the industry. Based on the product, the threshold suspend device system is expected to account for 72.5% of the global market share in 2025.
| Product | Threshold Suspend Device System |
|---|---|
| Value Share (2025) | 72.5% |
The threshold suspend device system is leading the artificial pancreas device system (APDS) market due to its unique ability to automatically stop insulin delivery when the blood glucose level reaches a predefined threshold, preventing hypoglycemia (low blood sugar).
This automatic response system significantly reduces the risk of dangerous hypoglycemic episodes, making it highly attractive to patients who need continuous glucose management but struggle with the risk of low blood sugar. Compared to more complex bi-hormonal control systems, the threshold suspend device offers a simpler and more affordable solution.
This makes it a popular choice for patients seeking effective glycemic control without the high costs associated with more advanced systems. Overall, the threshold suspend device system provides immediate protection against hypoglycemia, ease of use, and cost-effectiveness, placing it as one of the leading choices in the artificial pancreas device system market.
| Indication | Diabetes Type I |
|---|---|
| Value Share (2025) | 56.3% |
Type I diabetes is anticipated to grow at a CAGR of 5.3% throughout the forecast period.
Indication-wise, the dominant segment of the APDS market is dominated by type 1 diabetes, mainly on account of high disease prevalence and the requirement for a somewhat different line of treatment.
Accounting for about 5-10% of all diabetes cases in the world, type 1 diabetes is a form of autoimmune disease wherein the human immune system begins to attack the cells of the pancreas that make insulin, thereby disturbing its normal function related to blood sugar management. Thus, patients with Type 1 diabetes must undergo lifelong insulin therapy and aggressive management to delay the oncoming complications.
This high prevalence and chronicity put an immense demand for Type 1 artificial pancreas devices. The artificial pancreas device's design ensures automated insulin delivery adjustments according to instantaneous readings of glucose presentation, and these are must-have gadgets for anyone coping with Type 1 diabetes.
APDS devices have found their place in managing Type 1 diabetes, with the increasing demand for more effective and convenient solutions to manage blood glucose levels.
Therefore, this artificial pancreas device system market is highly competitive, with many key players actively working hard to maintain and even enhance their market positions. Major players in this industry are concentrating on innovation and investing highly in more advanced technologies and applications to cater to the different needs of healthcare providers and patients.
Such strategic approaches include forming regulatory approvals, strategic mergers, and expansions to expand such companies' product portfolios and geographic reach.
Recent Industry Developments in Artificial Pancreas Device System Market
In terms of product, the industry is divided into threshold suspend device system, insulin only system and bi-hormonal control system.
In terms of indication, the industry is divided into diabetes type I, diabetes type II and gestational diabetes.
In terms of end user, the industry is divided into hospitals, homecare settings, diabetes clinics, specialty clinics and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global artificial pancreas device system industry is projected to witness CAGR of 8.7% between 2025 and 2035.
The global artificial pancreas device system industry stood at USD 343.5 million in 2024.
The global artificial pancreas device system industry is anticipated to reach USD 875.3 million by 2035 end.
France is expected to show a CAGR of 5.9% in the assessment period.
The key players operating in the global artificial pancreas device system industry include Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., Abbott Laboratories, Beta Bionics, BigFoot Biomedical Inc., Diabeloop SA, EoFlow Co. Ltd, Inreda Diabetic B.V. among others.
| Estimated Market Size (2024E) | USD 2.2 billion |
|---|---|
| Projected Market Value (2034F) | USD 2.8 billion |
| Value-based CAGR (2024 to 2034) | 2.3% |
| Market Size, 2023 | USD 16.5 Million |
|---|---|
| Market Size, 2033 | USD 36.2 Million |
| Value CAGR (2023 to 2033) | 8.1% |
| Projected Value (2032) | USD 567.4 Million |
|---|---|
| Value-based CAGR | 12% |
Explore Therapeutic Device Insights
View Reports
Artificial Pancreas Device System Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
